£32,780-£41,093 per annum + benefits: Wellcome Sanger Institute: The opportunity: The Bayraktar and Stegle groups are seeking a computational postdoctoral fellow to explore how the tumour microenvironment (TME) d... Cambridge, Cambridgeshire

Notice NOT-TR-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-004 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-070 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-ES-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-022 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-021 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-011 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-010 from the NIH Guide for Grants and Contracts

£45000 - £55000 per annum: CK Group: CK Group are recruiting for a Bioinformatician to join a company in the biotech industry at their site based in London on a on a... London

Funding Opportunity PAR-22-028 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Funding Opportunity PAR-22-030 from the NIH Guide for Grants and Contracts. The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Funding Opportunity PAR-21-353 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Funding Opportunity PAR-21-354 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Funding Opportunity PAR-21-355 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Notice NOT-NR-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-020 from the NIH Guide for Grants and Contracts